Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Pediatr ; 261: 113549, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37301281

RESUMEN

OBJECTIVE: To develop a complexity scoring system to characterize the diverse population served in pediatric aerodigestive clinics and help predict their treatment outcomes. STUDY DESIGN: A 7-point medical complexity score was developed through an iterative group consensus of relative stakeholders to capture the spectrum of comorbidities among the aerodigestive population. One point was assigned for each comorbid diagnosis in the following categories: airway anomaly, neurologic, cardiac, respiratory, gastrointestinal, genetic diagnoses, and prematurity. A retrospective chart review was conducted of patients seen in the aerodigestive clinic who had ≥2 visits between 2017 and 2021. The predictive value of the complexity score for the selected outcome of feeding progression among children with dysphagia was analyzed with univariate and multivariable logistic regression. RESULTS: We analyzed 234 patients with complexity scores assigned, showing a normal distribution (Shapiro Wilk P = .406) of the scores 1-7 (median, 4; mean, 3.50 ± 1.47). In children with dysphagia, there was waning success in the improvement of oral feeding with increasing complexity scores (OR, 0.66; 95% CI, 0.51-0.84; P = .001). Tube-fed children with higher complexity scores were incrementally less likely to achieve full oral diet (OR, 0.60; 95% CI, 0.40-0.89; P = .01). On multivariable analysis, neurologic comorbidity (OR, 0.26; P < .001) and airway malformation (OR, 0.35; P = .01) were associated with a decreased likelihood to improve in oral feeding. CONCLUSIONS: We propose a novel complexity score for the pediatric aerodigestive population that is easy to use, successfully stratifies diverse presentations, and shows promise as a predictive tool to assist in counseling and resource use.


Asunto(s)
Trastornos de Deglución , Niño , Humanos , Trastornos de Deglución/epidemiología , Trastornos de Deglución/diagnóstico , Estudios Retrospectivos , Nutrición Enteral , Comorbilidad , Instituciones de Atención Ambulatoria
3.
J Clin Anesth ; 97: 111529, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-38878621

RESUMEN

STUDY OBJECTIVE: Postoperative nausea and vomiting (PONV) is a common sequela of surgery in patients undergoing general anesthesia. Amisulpride has shown promise in its ability to treat PONV. The objective of this study was to determine if amisulpride is associated with significant changes in PACU efficiency within a fast-paced ambulatory surgery center. METHODS: This was a retrospective cohort study of 816 patients at a single ambulatory surgery center who experienced PONV between 2018 and 2023. The two cohorts analyzed were patients who did or did not have amisulpride among their anti-emetic regimens in the PACU during two distinct time periods (before and after amisulpride was introduced). The primary outcome of the study was PACU length of stay. Both unmatched analysis and a linear multivariable mixed-effects model fit by restricted maximum likelihood (random effect being surgical procedure) were used to analyze the association between amisulpride and PACU length of stay. We performed segmented regression to account for cohorts occurring during two time periods. RESULTS: Unmatched univariate analysis revealed no significant difference in PACU length of stay (minutes) between the amisulpride and no amisulpride cohorts (115 min vs 119 min, respectively; P = 0.07). However, when addressing confounders by means of the mixed-effects multivariable segmented regression, the amisulpride cohort was associated with a statistically significant reduction in PACU length of stay by 26.1 min (P < 0.001). CONCLUSIONS: This study demonstrated that amisulpride was associated with a significant decrease in PACU length of stay among patients with PONV in a single outpatient surgery center. The downstream cost-savings and operational efficiency gained from this drug's implementation may serve as a useful lens through which this drug's widespread implementation may further be rationalized.


Asunto(s)
Procedimientos Quirúrgicos Ambulatorios , Amisulprida , Antieméticos , Tiempo de Internación , Náusea y Vómito Posoperatorios , Humanos , Náusea y Vómito Posoperatorios/epidemiología , Femenino , Masculino , Tiempo de Internación/estadística & datos numéricos , Estudios Retrospectivos , Persona de Mediana Edad , Amisulprida/administración & dosificación , Amisulprida/efectos adversos , Procedimientos Quirúrgicos Ambulatorios/efectos adversos , Adulto , Antieméticos/uso terapéutico , Antieméticos/administración & dosificación , Antieméticos/efectos adversos , Sala de Recuperación/estadística & datos numéricos , Anciano , Anestesia General/efectos adversos , Anestesia General/métodos , Resultado del Tratamiento , Periodo de Recuperación de la Anestesia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA